Cargando…

Correction: Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254139/ https://www.ncbi.nlm.nih.gov/pubmed/32448800 http://dx.doi.org/10.1136/jitc-2019-000319corr1

Ejemplares similares

Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma
por: Labriola, Matthew Kyle, et al.
Publicado: (2020)

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
por: Morrison, Carl, et al.
Publicado: (2018)

Author Correction: Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
por: Patterson, Andrew, et al.
Publicado: (2023)

DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden
por: Hsiehchen, David, et al.
Publicado: (2020)

Correction: Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
por: Makrakis, Dimitrios, et al.
Publicado: (2023)

Correction to: Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
por: Ornstein, Moshe C., et al.
Publicado: (2023)

Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
por: Burcher, Kimberly M., et al.
Publicado: (2021)

Correction: Chronic immune checkpoint inhibitor pneumonitis
Publicado: (2020)

Correction: Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer
por: Gao, Mei, et al.
Publicado: (2020)

Correction: Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers
Publicado: (2021)

Correction: Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis
por: Reddy, Haritha G., et al.
Publicado: (2018)

Correction: Efficacy of immune checkpoint inhibitors for in-transit melanoma
Publicado: (2020)

Correction: Immune checkpoint inhibitor-associated celiac disease
Publicado: (2020)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Correction: MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy
Publicado: (2020)

Correction: Acute kidney injury in patients treated with immune checkpoint inhibitors
Publicado: (2023)

Author Correction: Chlorin e6-associated photodynamic therapy enhances abscopal antitumor effects via inhibition of PD-1/PD-L1 immune checkpoint
por: Gurung, Pallavi, et al.
Publicado: (2023)

Publisher Correction: Base excision repair AP endonucleases and mismatch repair act together to induce checkpoint-mediated autophagy
por: SenGupta, Tanima, et al.
Publicado: (2018)

Correction: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
por: Oner, Gizem, et al.
Publicado: (2023)

Correction: Erlichman et al. Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes. Cancers 2022, 14, 1042
por: Erlichman, Nofar, et al.
Publicado: (2022)

Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
por: Anand, Kartik, et al.
Publicado: (2020)

Correction: DNA Damage, Homology-Directed Repair, and DNA Methylation
por: Cuozzo, Concetta, et al.
Publicado: (2017)

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden
por: Quintanilha, Julia C. F., et al.
Publicado: (2023)

Correction to: DNA mismatch repair in the context of chromatin
por: Huang, Yaping, et al.
Publicado: (2020)

Correction: Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Publicado: (2022)

Correction: COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report
Publicado: (2021)

A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer
por: Fan, Zhongyuan, et al.
Publicado: (2019)

Correction: Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease
por: Mijuskovic, Martina, et al.
Publicado: (2019)

Correction: PD − L1 immunostaining: what pathologists need to know
por: Akhtar, Mohammed, et al.
Publicado: (2022)

Correction: Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1
Publicado: (2022)

Correction: HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma
Publicado: (2020)

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
por: Akinleye, Akintunde, et al.
Publicado: (2019)

Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

Correction: Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
por: Chu, Xianjing, et al.
Publicado: (2023)

Correction: PLK1/vimentin signaling facilitates immune escape by recruiting Smad2/3 to PD-L1 promoter in metastatic lung adenocarcinoma
por: Jang, Hay-Ran, et al.
Publicado: (2021)

Correction: Desperately seeking…Models to find the right partner and the best use for checkpoint inhibitors
por: Bertolini, Francesco
Publicado: (2019)

Correction: Desperately seeking…Models to find the right partner and the best use for checkpoint inhibitors
por: Bertolini, Francesco
Publicado: (2019)

Correction: On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19
Publicado: (2021)

Correction to: Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer
por: Wang, Peiliang, et al.
Publicado: (2021)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_smmilcrlni11mheirqk6tu1trs